- Home
- PRPO vs CARM Comparison
PRPO vs CARM Comparison
Compare PRPO & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- CARM
- Stock Information
- Founded
- PRPO N/A
- CARM 2016
- Country
- PRPO United States
- CARM United States
- Employees
- PRPO N/A
- CARM N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- CARM Health Care
- Exchange
- PRPO Nasdaq
- CARM Nasdaq
- Market Cap
- PRPO 17.1M
- CARM 16.4M
- IPO Year
- PRPO N/A
- CARM N/A
- Fundamental
- Price
- PRPO $14.45
- CARM $0.41
- Analyst Decision
- PRPO
- CARM Hold
- Analyst Count
- PRPO 0
- CARM 5
- Target Price
- PRPO N/A
- CARM $0.90
- AVG Volume (30 Days)
- PRPO 17.7K
- CARM 2.1M
- Earning Date
- PRPO 08-12-2025
- CARM 08-07-2025
- Dividend Yield
- PRPO N/A
- CARM N/A
- EPS Growth
- PRPO N/A
- CARM N/A
- EPS
- PRPO N/A
- CARM N/A
- Revenue
- PRPO $20,029,000.00
- CARM $19,964,000.00
- Revenue This Year
- PRPO N/A
- CARM N/A
- Revenue Next Year
- PRPO N/A
- CARM N/A
- P/E Ratio
- PRPO N/A
- CARM N/A
- Revenue Growth
- PRPO 26.67
- CARM 32.45
- 52 Week Low
- PRPO $3.90
- CARM $0.14
- 52 Week High
- PRPO $16.89
- CARM $1.38
- Technical
- Relative Strength Index (RSI)
- PRPO 68.17
- CARM 51.78
- Support Level
- PRPO $14.25
- CARM $0.38
- Resistance Level
- PRPO $16.89
- CARM $0.42
- Average True Range (ATR)
- PRPO 1.08
- CARM 0.04
- MACD
- PRPO 0.24
- CARM -0.01
- Stochastic Oscillator
- PRPO 67.57
- CARM 43.23
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.